-
[show abstract]
[hide abstract]
ABSTRACT: We carried out retrospective analysis of apparent diffusion coefficient (ADC) values in 48 infiltrating ductal breast cancer patients who had dynamic contrast-enhanced magnetic resonance imaging (DCEMRI; Group I) and in 53 patients (Group II) for whom DCEMRI data were not available. Twenty-three patients of Group I showed no necrosis (Group Ia), while in 25 patients, both viable (nonnecrotic) and necrotic tumor areas (Group Ib) were observed on DCEMRI. T1-weighted, fat-suppressed and short inversion recovery images were used to identify the viable and necrotic tumor areas in Group II patients, and necrosis was not seen in 11 patients (Group IIa), while 42 (Group IIb) showed both viable and necrotic tumor areas. The ADCs of the necrotic area of Group Ib (1.79±0.30 ×10(-3) mm(2)/s) and Group IIb (1.83±0.40 ×10(-3) mm(2)/s) patients were similar and significantly higher (P<.01) compared to the ADCs of the viable tumor area of Group Ia (0.96±0.21 ×10(-3) mm(2)/s) and Group IIa (0.90±0.17 ×10(-3) mm(2)/s) patients. Proton MR spectroscopy (MRS) data were also available in these patients, and the ADC values were retrospectively determined from the voxel from which MR spectrum was obtained. These values were compared with the ADC obtained for the viable and necrotic areas of the tumor. ADC of the MRS voxel was similar to that obtained for the viable tumor area in patients of both groups. This interesting observation reveals the potential utility of using ADC values to identify viable tumor area for positioning of voxel for MRS in the absence of DCEMRI data.
Magnetic Resonance Imaging 03/2012; 30(5):649-55. · 1.99 Impact Factor
-
03/2010; , ISBN: 9780470034590
-
[show abstract]
[hide abstract]
ABSTRACT: Breast cancer is a major health problem in women, worldwide. A combination of physical examination, mammography, ultrasound and fine needle aspiration cytology (FNAC) or core biopsy is currently the mainstay for preoperative diagnosis of breast lesions. Magnetic resonance imaging (MRI) has been proposed as a useful complimentary modality to provide additional information. It has shown potential in the detection, diagnosis and management of breast cancer. It can be used to improve preoperative staging, follow response to therapy, and to detect local recurrences. Contrast enhanced MRI (CEMRI) has evolved as an important tool in the evaluation of breast abnormalities with high sensitivity (94-100%), but with poor specificity. Recently, diffusion and perfusion MRI techniques have been applied to breast lesion characterization and show promise but warrant further investigations. Characterization of breast lesions may also be assisted by using information of the cellular chemistry provided by in vivo proton MR spectroscopy (MRS). Recent reports have shown that neoplastic breast tissue contains elevated levels of choline containing compounds, which can be used as a biochemical marker for differentiating benign versus malignant tumor and for monitoring treatment response. Presently, the various MR techniques show promise primarily as adjunct to the existing standard detection techniques, and its acceptability as a primary screening method will increase only if specificity can be increased. This review presents the current status of MRI and MRS in breast imaging.
Current Medical Imaging Reviews 07/2006; 2(3):329-340. · 0.71 Impact Factor
